MAYO CLINIC

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1889-01-01

Employees: 10K

Market Cap: -

Website: http://www.mayoclinic.org

Clinical Trials

Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma

Phase 1

Completed

Conditions: Refractory Plasma Cell Myeloma
Recurrent Plasma Cell Myeloma

Interventions: Other: Laboratory Biomarker Analysis
Drug: Cyclophosphamide
Biological: Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter
Other: Pharmacological Study

First Posted Date: 2007-03-22

Last Posted Date: 2019-12-16

Lead Sponsor: Mayo Clinic

Target Recruit Count: 48

Registration Number: NCT00450814

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Thalidomide, Prednisone, and Cyclophosphamide in Treating Patients With Myelofibrosis and Myeloid Metaplasia

Phase 2

Completed

Conditions: Chronic Myeloproliferative Disorders
Secondary Myelofibrosis

First Posted Date: 2007-03-09

Last Posted Date: 2011-03-17

Lead Sponsor: Mayo Clinic

Target Recruit Count: 22

Registration Number: NCT00445900

Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profiles Associated With Insulin Resistance

Phase 2

Completed

Conditions: Type 2 Diabetes
Insulin Resistance
Metabolic Syndrome

Interventions: Drug: Placebo
Drug: metformin
Drug: pioglitazone

First Posted Date: 2007-03-06

Last Posted Date: 2013-10-31

Lead Sponsor: Mayo Clinic

Target Recruit Count: 28

Registration Number: NCT00443755

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Determination of Adipocyte Parameters in Iliac Crest Biopsies From Post Menopausal Women

Not Applicable

Completed

Conditions: Osteoporosis
Postmenopausal

First Posted Date: 2007-03-06

Last Posted Date: 2010-01-15

Lead Sponsor: Mayo Clinic

Target Recruit Count: 60

Registration Number: NCT00443716

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Alefacept in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma or Peripheral T-Cell Non-Hodgkin's Lymphoma

Phase 1

Completed

Conditions: Lymphoma

Interventions: Drug: Alefacept

First Posted Date: 2007-02-22

Last Posted Date: 2019-08-13

Lead Sponsor: Mayo Clinic

Target Recruit Count: 23

Registration Number: NCT00438802

Locations: 🇺🇸
Mayo Clinic Cancer Center, Rochester, Minnesota, United States
🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
Holden Comprehensive Cancer Center at University of Iowa, Iowa City, Iowa, United States

Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma

Phase 1

Completed

Conditions: Nodal Marginal Zone Lymphoma
Recurrent Grade 1 Follicular Lymphoma
Recurrent Grade 3 Follicular Lymphoma
Recurrent Mantle Cell Lymphoma
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
Recurrent Grade 2 Follicular Lymphoma
Waldenstrom Macroglobulinemia
Recurrent Marginal Zone Lymphoma
Adult Non-Hodgkin Lymphoma
Recurrent Adult Diffuse Large Cell Lymphoma

Interventions: Drug: Agatolimod Sodium
Radiation: Indium In-111 Ibritumomab Tiuxetan
Other: Laboratory Biomarker Analysis
Procedure: Radionuclide Imaging
Biological: Rituximab
Procedure: Single Photon Emission Computed Tomography
Radiation: Yttrium Y-90 Ibritumomab Tiuxetan

First Posted Date: 2007-02-22

Last Posted Date: 2016-02-04

Lead Sponsor: Mayo Clinic

Target Recruit Count: 38

Registration Number: NCT00438880

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸
University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States

Islet Transplantation for Type 1 Diabetes Mellitus

Phase 1

Terminated

Conditions: Type 1 Diabetes Mellitus

Interventions: Biological: Islet Transplant

First Posted Date: 2007-02-21

Last Posted Date: 2013-04-25

Lead Sponsor: Mayo Clinic

Target Recruit Count: 2

Registration Number: NCT00437398

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery

Phase 2

Completed

Conditions: Cardiac Toxicity
Breast Cancer

First Posted Date: 2007-02-19

Last Posted Date: 2022-08-05

Lead Sponsor: Mayo Clinic

Target Recruit Count: 122

Registration Number: NCT00436566

Locations: 🇺🇸
Mayo Clinic Cancer Research Consortium, Rochester, Minnesota, United States

Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous Treatment

Phase 2

Completed

Conditions: Leukemia
Lymphoma
Lymphoproliferative Disorder

Interventions: Drug: Everolimus

First Posted Date: 2007-02-19

Last Posted Date: 2019-10-22

Lead Sponsor: Mayo Clinic

Target Recruit Count: 277

Registration Number: NCT00436618

Locations: 🇺🇸
Mayo Clinic Scottsdale, Scottsdale, Arizona, United States
🇺🇸
Mayo Clinic Cancer Center, Rochester, Minnesota, United States
🇺🇸
Mayo Clinic - Jacksonville, Jacksonville, Florida, United States

Lapatinib and Topotecan in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Did Not Respond to Cisplatin or Carboplatin

Phase 2

Completed

Conditions: Ovarian Cancer
Peritoneal Cavity Cancer

Interventions: Drug: Lapatinib
Drug: Topotecan

First Posted Date: 2007-02-19

Last Posted Date: 2014-04-16

Lead Sponsor: Mayo Clinic

Target Recruit Count: 18

Registration Number: NCT00436644

Locations: 🇺🇸
Mayo Clinic Cancer Center, Rochester, Minnesota, United States
🇺🇸
Mayo Clinic Arizona, Scottsdale, Arizona, United States
🇺🇸
Mayo Clinic in Jacksonville, Jacksonville, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy